COVAXIN exhibits interim efficacy of 81% in part 3 scientific trials

Image Source : FILE PHOTO COVAXIN exhibits interim efficacy of 81 per cent in part 3 scientific outcomes, says Bharat Biotech.
India’s indigenously developed vaccine towards coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 scientific trial. The trials concerned 25,800 topics, the most important ever performed in India, in partnership with ICMR, knowledgeable vaccine maker Bharat Biotech.

Covaxin is India’s completely indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.

The vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility, one among its sort on this planet.
Latest India News